Mersana Therapeutics, Inc. (MRSN)
Chart Events
Performance Outlook
| Previous Close | 6.15 |
| Open | 6.16 |
| Bid | 6.46 x 3100 |
| Ask | 6.47 x 2900 |
| Day's Range | 6.15 - 6.46 |
| 52 Week Range | 2.68 - 10.06 |
| Volume | |
| Avg. Volume | 1,356,761 |
| Market Cap | 459.516M |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.43 |
| Earnings Date | Feb 24, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.00 |
- GlobeNewswire
Mersana Therapeutics Announces FDA Fast Track Designation Granted to XMT-1660 for the Treatment of Triple-Negative Breast Cancer
XMT-1660 currently being studied in a Phase 1 trial enrolling patients with breast, endometrial and ovarian cancersCAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XMT-
- GlobeNewswire
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at two upcoming investor conferences. Details are as follows: Morgan Stanley 20th Annual Global Healthcare ConferenceFormat: Fireside Chat Date/Time: Monday, Septembe
- GlobeNewswire
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on September 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 25
